Pathogenesis and treatment of multiple myeloma bone disease

Masahiro Hiasa; Takeshi Harada; Eiji Tanaka; Masahiro Abe

doi:10.1016/j.jdsr.2021.08.006

Pathogenesis and treatment of multiple myeloma bone disease

Jpn Dent Sci Rev. 2021 Nov:57:164-173. doi: 10.1016/j.jdsr.2021.08.006. Epub 2021 Sep 23.

Authors

Masahiro Hiasa¹, Takeshi Harada², Eiji Tanaka¹, Masahiro Abe²

Affiliations

¹ Department of Orthodontics and Dentofacial Orthopedics, Tokushima University, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.
² Department of Hematology, Endocrinology and Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.

Abstract

Multiple myeloma (Plasma cell myeloma), a malignancy of the plasma cells, exhibits tumor expansion preferentially in the bone marrow and the development of bone-destructive lesions. Multiple myeloma is still an incurable disease with changes in the bone marrow microenvironment in favor of the survival and proliferation of multiple myeloma cells and bone destruction. In this review, we described the recent findings on the regulators involved in the development of myeloma bone diseases, and succinctly summarize currently available therapeutic options and the development of novel bone modifying agents for myeloma treatment.

Keywords: Bone diseases; Multiple myeloma (Plasma cell myeloma); Osteoblasts; Osteoclasts; Osteocytes.

Publication types

Review